Determinants of weight gain in the action to control cardiovascular risk in diabetes trial.
about
Sodium-glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin-metforminEfficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).Systolic Blood Pressure Control Among Individuals With Type 2 Diabetes: A Comparative Effectiveness Analysis of Three Interventions.Predictors of longterm changes in body mass index in rheumatoid arthritis.Nutrition therapy recommendations for the management of adults with diabetes.Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥65 and <65 years.Composite endpoints in trials of type-2 diabetes.Glucose targets for preventing diabetic kidney disease and its progression.Metformin: an Old Therapy that Deserves a New Indication for the Treatment of Obesity.What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?Factors associated with failure to achieve a glycated haemoglobin target of <8.0% in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.Effects of insulin therapy on weight gain and fat distribution in the HF/HS-STZ rat model of type 2 diabetes.Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in Type 2 diabetes: a network meta-analysis.Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy.
P2860
Q26752815-20D9D7A1-7F43-4D97-84A0-42D792BB70AAQ33960291-01021905-30FE-43B0-BB05-2B143828E707Q35862979-43508F6C-AB99-4907-9015-9AB8B993590CQ36784187-92AF7A7E-B6D1-4EE3-9A56-4FE576D21C8EQ37278232-1D2468F3-09EA-4333-85B1-ADFD0B6CDA38Q37384963-D414305F-3E72-4AAC-B6DF-3591600FEAD8Q38154679-CAE26975-DF2A-4B84-87FC-8FC6B7DCC25DQ38736800-8CBD40E8-2E14-4E8A-8DE1-E02222363661Q38737909-2C1B5137-EA32-4E72-82D9-8FAC34D44FBCQ38931845-4DA8B994-C471-4E1C-AA1F-19EB09297FF0Q40468686-88135976-3E61-4C7F-9C6B-8B352CB9C82EQ40785914-236F9FED-DE71-4146-AAC4-6AFCB9A0244CQ40806756-C9623B75-56D7-4C21-849D-A541A4D4EFC2Q48280522-157D643A-9322-4D74-A6CD-3630969FFD03
P2860
Determinants of weight gain in the action to control cardiovascular risk in diabetes trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 February 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Determinants of weight gain in ...... scular risk in diabetes trial.
@en
Determinants of weight gain in ...... scular risk in diabetes trial.
@nl
type
label
Determinants of weight gain in ...... scular risk in diabetes trial.
@en
Determinants of weight gain in ...... scular risk in diabetes trial.
@nl
prefLabel
Determinants of weight gain in ...... scular risk in diabetes trial.
@en
Determinants of weight gain in ...... scular risk in diabetes trial.
@nl
P2093
P2860
P356
P1433
P1476
Determinants of weight gain in ...... scular risk in diabetes trial.
@en
P2093
ACCORD Study Group
Faramarz Ismail-Beigi
Jorge Calles
Mark Feinglos
Matthew C Riddle
Patricia Feeney
Robert M Cohen
Roberta McDuffie
Timothy M Morgan
Vivian Fonseca
P2860
P304
P356
10.2337/DC12-1391
P407
P577
2013-02-14T00:00:00Z